[
    [
        {
            "time": "2023-10-01",
            "original_text": "Eli Lilly Stock Soars To 96 Composite Rating",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Stock Soars",
                    "Composite Rating"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly Stock Soars To 96 Composite Rating",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-02",
            "original_text": "Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer",
            "features": {
                "keywords": [
                    "Innovent",
                    "Sintilimab",
                    "Overall Survival Benefit",
                    "Gastric Cancer"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-03",
            "original_text": "Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials",
            "features": {
                "keywords": [
                    "Lilly",
                    "Lebrikizumab",
                    "Clinical Benefit",
                    "Atopic Eczema",
                    "Trials"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "dermatology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-04",
            "original_text": "FDA Approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for Use in Insulin Pumps",
            "features": {
                "keywords": [
                    "FDA",
                    "Approves",
                    "Lyumjev",
                    "Insulin Pumps"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "diabetes care"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "FDA Approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for Use in Insulin Pumps",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials",
            "features": {
                "keywords": [
                    "Lilly",
                    "lebrikizumab",
                    "skin clearance",
                    "itch",
                    "atopic dermatitis",
                    "Phase 3 trials"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "dermatology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]